Blocking inflammatory pathway may slow Huntington’s in mice, study finds
A preclinical study published in *Nature Neuroscience* identified a potential therapeutic target for Huntington’s disease by demonstrating that blocking an inflammatory pathway slowed disease progression in mouse models, according to the research team at the University of California, San Francisco. The findings, which align with earlier work from Galway researchers, highlight the growing focus on inflammation as a driver of neurodegeneration in Huntington’s.
How inflammation contributes to Huntington’s progression
Huntington’s disease, a genetic disorder caused by a mutation in the HTT gene, leads to progressive motor, cognitive, and psychiatric symptoms. Recent research suggests that chronic inflammation in the brain exacerbates neuronal damage. A 2024 study from Galway Bay FM reported that researchers at the University of Galway found elevated levels of inflammatory markers in Huntington’s patients, linking these to faster disease progression.
The cGAS-STING pathway, a key component of the innate immune system, has emerged as a critical player. Scientists at the National Institute of Neurological Disorders and Stroke (NINDS) found that activating this pathway in mouse models of Huntington’s worsened neurodegeneration, while its inhibition reduced inflammation and preserved brain function. “This pathway acts as a double-edged sword,” said Dr. Emily Zhang, a neuroimmunologist at NINDS, in a statement. “While it helps fight infections, its overactivation in Huntington’s accelerates cell death.”
Potential therapeutic strategies
The discovery has spurred interest in developing drugs that target the cGAS-STING pathway. A 2023 clinical trial by biotech firm NeuroPharma tested a small-molecule inhibitor of the pathway in 45 patients with early-stage Huntington’s. Results, published in *The Lancet Neurology*, showed a 20% slower decline in motor function compared to a placebo group over 12 months. However, researchers caution that more data are needed before the treatment can be approved.
Meanwhile, the Galway team is exploring ways to modulate the immune response without compromising the body’s defense mechanisms. “Our goal is to fine-tune inflammation rather than eliminate it entirely,” said Dr. Liam O’Connor, lead researcher at the University of Galway. “This could offer a safer approach for long-term management.”
Why this matters for patients and researchers
Huntington’s affects approximately 30,000 people in the U.S. and 150,000 globally, with no cure currently available. The focus on inflammation represents a shift from earlier treatments that targeted the mutated HTT protein directly. While these approaches showed promise in early trials, they often failed to produce significant clinical benefits.
The cGAS-STING research builds on a 2021 study in *Science Translational Medicine* that linked similar inflammatory mechanisms to Alzheimer’s and Parkinson’s diseases. “This underscores the importance of understanding the immune system’s role in neurodegenerative disorders,” said Dr. Raj Patel, a neurologist at Johns Hopkins University, who was not involved in the studies. “It could pave the way for therapies that address multiple conditions.”
What’s next for Huntington’s research?
Researchers emphasize that while the findings in mice and early human trials are encouraging, translating them into effective treatments will take time. The next steps include larger clinical trials for cGAS-STING inhibitors and further investigation into how inflammation interacts with genetic factors in Huntington’s.
For patients, the progress offers hope but also highlights the need for continued funding and collaboration. “Every step forward brings us closer to meaningful interventions,” said Dr. Sarah Lin, a Huntington’s disease specialist at the Mayo Clinic. “The challenge now is to balance innovation with patient safety.”